ESEun Ji Shin

Eun Ji Shin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Eun Ji Shin has a total of 604 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Association of obstructive sleep apnea with pancreatic cancer in high-risk patients under surveillance in CAPS and PCYST cohorts

    by Hassan Sinan, Emy Abou Sleiman, Amanda L. Blackford, Takahiro Shinozuka, Dimitri Melki, Jad Saab, Michael Romanos, Kylie Ning, Michel Almardini, Andrea Castellino, et al.

  • Open Access

    International Case-Control Study of DNA Methylation Biomarkers for the Minimally Invasive Diagnosis of Esophageal Squamous Cell Carcinoma

    by Yulan Cheng, Adithi Banavar, Ke Ma, Paul Stephen Obwoya, Kija Luhuti, Caleb Tuhumwire, Shayan Gheshlaghi, Kelly Fan, Yifan Yang, Kuangwen Hsieh, et al.

    INTRODUCTION: Esophageal squamous cell carcinoma (ESCC), the most common type of esophageal cancer worldwide, is usually diagnosed by esophagogastroduodenoscopy, an expensive procedure having limited availability in low- and middle-income countries. We therefore developed a diagnostic strategy that applies ESCC-specific DNA methylation biomarkers to nonendoscopically-obtained esophageal mucosal samples. METHODS: We used a novel approach based on a search of 5 publicly available GEO and TCGA datasets, which contained 196 organ-specific normal controls. We selected 6 new methylation markers, combining these with 5 markers identified in a previous study. We then performed a case-control analysis of 174 esophageal cytologic samples collected using a swallowable sponge-capsule device, one sample each from 93 patients with ESCC and 81 noncancer control patients. Based on these molecular data, a classification algorithm was built in a training set of 122 patients using the least absolute shrinkage and selection operator (LASSO) method, which was then tested in a separate cohort of 52 patients. Coefficients of the LASSO regression model were used to select markers that contributed most strongly to the classification. RESULTS: All 11 markers tested exhibited significantly higher methylation levels in all 93 ESCC sponge samples than in 81 normal control sponges, with P -values below 0.001. Furthermore, individual areas under the receiver operating characteristic curve (AUCs) for the 11 markers, C1ORF70, PPFIA3, SKOR1, ZNF132, TAC1, JPH4, ZNF542, KLF16, CG20655070, SLC35, and PAX9, were 0.91, 0.90, 0.89, 0.89, 0.89, 0.89, 0.87, 0.87, 0.83, 0.82, 0.81, and 0.65, respectively. Based on LASSO regression applied to all 11 markers, 4 (C1ORF70, CG20655070, SKOR1, and PPFIA3) were retained in our final model. A composite score based on this final model achieved an area under the receiver operating characteristic curve of 0.93 in the 122-patient training cohort and 0.92 in the 52-patient test set. DISCUSSION: When used in combination with a minimally invasive sponge-capsule device, ESCC methylation biomarkers may improve the diagnosis of ESCC. This strategy harbors potential to mitigate the deadly worldwide public health impact of ESCC.

  • Endoscopic Ultrasound-Guided Gallbladder Drainage

    by Andrew Canakis, Todd H. Baron, Shifa Umar, Gregory Lam, Rahul Pannala, Stuart Amateau, Thomas Tielleman, Dmitriy O. Khodorskiy, Rafael Ching Companioni, Gurneet Bedi, et al.

    Acute cholecystitis affects ∼200,000 individuals annually in the United States, with laparoscopic cholecystectomy as the gold standard treatment. However, in high-risk surgical candidates, alternative drainage methods are necessary. Percutaneous transhepatic gallbladder drainage (PT-GBD) has traditionally served as the primary alternative intervention, offering rapid decompression, but is limited by a negative impact on the patient’s quality of life, the risk of long-term or even permanent tube placement, adverse events, and high recurrence rates. Endoscopic approaches, such as endoscopic transpapillary gallbladder drainage (ET-GBD) and, more recently, endoscopic ultrasound-guided gallbladder drainage (EUS-GBD), have emerged as viable alternatives to PT-GBD. EUS-GBD, first introduced in 2007, offers technical and clinical outcomes comparable to PT-GBD with fewer adverse events, shorter hospital stays, and lower rates of recurrence. The introduction of lumen-apposing metal stents (LAMS) has revolutionized EUS-GBD, simplifying deployment and enabling subsequent internal gallbladder access, which allows additional interventions such as cholecystoscopy and stone removal. EUS-GBD is now supported by international guidelines, and 1 device has achieved FDA approval for the management of acute cholecystitis in nonsurgical candidates. Proper patient selection is essential, guided by multidisciplinary evaluation, with EUS-GBD contraindicated in specific scenarios such as gallbladder perforation, coagulopathy, and large-volume ascites. Technical considerations include choice of access site (transgastric versus transduodenal), stent type, and procedural route [direct (freehand) or wire-guided]. Postprocedural care and stent management remain variable and nonstandardized. Emerging data suggest that interval cholecystectomy can still be performed safely after EUS-GBD. As adoption of EUS-GBD with LAMS expands, structured training and standardization of practice are crucial to optimizing outcomes.


  • Feasibility and clinical utility of stone extraction balloon catheter-assisted endoscopic stenting for malignant distal duodenal and proximal jejunal obstruction (with video)

    by Jong Hoon Park, Young Rong Kim, Jae Chul Hwang, Kee Myung Lee, Byung Moo Yoo, Jin Hong Kim, Eun Ji Shin, Min Jae Yang

    Background Endoscopic stenting for malignant distal duodenal and jejunal obstructions is challenging because the length of conventional gastroscopes is insufficient to reach the obstruction point. A fully inflated balloon catheter freely navigates the duodenum and jejunum without causing bowel injury by burying the catheter tip. It easily changes its direction for guidewire relocation, conforming to the angulation of the small bowel flexures. This study evaluated the feasibility and efficacy of stone extraction balloon catheter-assisted endoscopic stenting for malignant distal duodenal and proximal jejunal obstructions. Methods Patients with malignant distal duodenal or jejunal obstructions who underwent stone extraction balloon catheter-assisted duodenal stenting between January 2015 and December 2022 were retrospectively analyzed. Results We evaluated 30 patients in this study. Pancreatic cancer is the primary cause of duodenal obstruction, with the third portion of the duodenum being the most common obstruction site. Technical success was achieved in 100% of cases, and the clinical success rate was 100%. The median procedure time was 35 min, and the mean gastric outlet obstruction score (GOOSS) improved from 1.20 (pre-procedure) to 2.87 (post-procedure). Early stent migration was encountered in one patient. During follow-up, stent dysfunction was noted in nine (30%) patients, and the overall stent patency time was 145 days. Conclusion Stone extraction balloon catheter-assisted endoscopic stenting is an effective and reproducible technique for treating malignant distal duodenal and jejunal obstructions. Graphical Abstract


  • Mechanistic loop-resolution strategies for short-type single-balloon enteroscopy-assisted ERCP in patients post Roux-en-Y hepaticojejunostomy with a preserved stomach and duodenum

    by Min Jae Yang, Woohyun Cho, Jae Chul Hwang, Byung Moo Yoo, Soon Sun Kim, Jin Hong Kim, Eun Ji Shin

    Endoscopic access in Roux-en-Y hepaticojejunostomy after bile duct resection is more challenging than Roux-en-Y reconstruction following gastrectomy or pancreaticoduodenectomy owing to unstable S-shaped loop formation across the preserved upper gastrointestinal structure. This study evaluated the feasibility of mechanistic loop-resolution strategies for short-type single-balloon enteroscopy (short SBE)-assisted endoscopic retrograde cholangiopancreatography (ERCP) in patients post Roux-en-Y hepaticojejunostomy with a preserved stomach and duodenum. Mechanistic loop resolution converted an S-shaped loop with two conflicting rotational vectors into a unidirectional rotational vector, forming either a J configuration or a ring-shaped loop. The short SBE approach was successful in 27 of 31 cases (87.1%). The mean time to reach the jejunojejunal and hepaticojejunal anastomoses was 24.3 minutes and 61.8 minutes, respectively. Biliary cannulation via the hepaticojejunostomy was successful in 96.6% of cases. The therapeutic success rate was 83.9% (26/31) for short SBE and 84.8% (28/33) when including both short and long SBE. The mean total procedure time was 95.9 minutes. Adverse events occurred in three patients (9.1%). Standardized mechanistic loop-resolution strategies yielded high success rates for the short SBE approach and ERCP in patients with a Roux-en-Y hepaticojejunostomy and a preserved stomach and duodenum.


  • Discovery of Methylated DNA Biomarkers for Potential Nonendoscopic Detection of Barrett's Esophagus and Esophageal Adenocarcinoma

    by Andrew Kalra, Ke Ma, Yulan Cheng, Hua-Ling Tsai, Hao Wang, Leslie Cope, Yifan Yang, Daniel Lunz, Sarah Laun, Lisa Kann, et al.

    INTRODUCTION: We sought to develop a minimally invasive, robust, accessible nonendoscopic strategy to diagnose Barrett's esophagus (BE), esophageal adenocarcinoma (EAC), and its immediate precursor lesion, high-grade dysplasia (HGD) based on methylated DNA biomarkers applied to a retrievable sponge-capsule device in a cohort representative of the BE population (i.e., mostly short-segment, nondysplastic BE [NDBE]). METHODS: We identified 12 candidate methylation markers to distinguish normal vs abnormal esophagus. These 12 markers were first assayed in 21-paired matched NDBE-normal esophageal tissues, then assessed in a case-control study of 234 esophageal samples collected using a sponge-capsule device. A classification algorithm was developed using the least absolute shrinkage and selection operator in a 199-patient training set and tested in an independent 35-patient test set. RESULTS: Twelve markers (A1BG, C9orf50, cg00720137, FLI1, GRAMD1B, HOXB13, IRF4, KCNQ3, NTNG1, SPX, TBC1D30, and USP44) were significantly hypermethylated (i.e., all P < 0.05) in BE vs matched normal esophageal biopsies. A discriminatory 3-gene least absolute shrinkage and selection operator panel (USP44, TBC1D30, and NELL1), adjusted for age and sex, accurately distinguished HGD or EAC from normal control patients in both training (area under the receiver operating characteristic curve [AUC] 0.911, 95% confidence interval [CI] 0.863–0.959) and test (AUC 0.969, 95% CI 0.911–1.00) sets. In normal vs NDBE/LGD/HGD/EAC patients, this algorithm exhibited AUCs of 0.862 (95% CI 0.812–0.912) and 0.864 (95% CI 0.745–0.982) in training and test sets, respectively. In normal vs NDBE patients, the algorithm yielded AUCs of 0.819 (95% CI 0.748–0.889) and 0.776 (95% CI 0.583–0.968) in training and test sets, respectively. DISCUSSION: This discriminatory biomarker panel algorithm exemplifies a practical nonendoscopic strategy to diagnose BE, HGD, and EAC using a minimally invasive sponge-capsule device coupled with DNA methylation markers.


  • Open Access

    Fecal Microbiome Composition Correlates with Pathologic Complete Response in Patients with Operable Esophageal Cancer Treated with Combined Chemoradiotherapy and Immunotherapy

    by Fyza Y. Shaikh, Seoho Lee, James R. White, Yujie Zhao, Jacqueline T. Ferri, Gavin Pereira, Blair V. Landon, Suqi Ke, Chen Hu, Josephine L. Feliciano, et al.

    Background: Preclinical and clinical data indicate that chemoradiotherapy (CRT) in combination with checkpoint inhibitors may prime an anti-tumor immunological response in esophageal cancer. However, responses to neoadjuvant therapy can vary widely and the key biomarkers to determine response remain poorly understood. The fecal microbiome is a novel and potentially modifiable biomarker of immunotherapy response, and both fecal and tumor microbes have been found to associate with outcomes in esophageal cancer. Methods: Fecal and tumor samples were collected from patients with stage II–III resectable esophageal or gastroesophageal junction carcinoma treated with neoadjuvant immune checkpoint inhibitors (ICIs) plus CRT prior to surgical resection. Microbiome profiles were analyzed by 16S rRNA amplicon sequencing and taxonomic data were integrated with fecal metabolite analysis to assess microbial function. Results: The fecal microbiome of patients with pathological complete response (PCR) grouped in distinct clusters compared to patients with residual viable tumor (RVT) by Bray–Curtis diversity metric. Integrated taxonomic and metabolomic analysis of fecal samples identified a sphingolipid and primary bile acid as enriched in the PCR, the levels of which correlated with several bacterial species: Roseburis inulinivorans, Ruminococcus callidus, and Fusicantenibacter saccharivorans. Analysis of the tumor microbiome profiles identified several bacterial genera previously associated with esophageal tumors, including Streptococcus and Veillonella. Conclusions: These results further characterize the fecal and tumor microbiome of patients with operable esophageal cancer and identify specific microbes and metabolites that may help elucidate how microbes contribute to tumor response with neoadjuvant CRT combined with ICI.


  • Open Access

    EUS-guided hydrogel injection to separate pancreatic head carcinoma from duodenum for enhanced radiotherapy: Multi-site feasibility study

    by Manoop S. Bhutani, Amol K. Narang, Kai Ding, Brenna Casey, Kumar Krishnan, Eugene J. Koay, Theodore S. Hong, Joseph M. Herman, Kristen H. Griffin, Eun Ji Shin

    Background and study aims The proximity of a pancreas head tumor to the duodenum often limits delivery of an ablative dose of radiation therapy. This study evaluated the feasibility and safety of using an injectable polyethylene glycol (PEG) hydrogel between the head of the pancreas and duodenum. Patients and methods In a multi-site feasibility cohort study of patients with localized pancreatic cancer, PEG hydrogel was injected under endoscopic ultrasound guidance to temporarily position the duodenum away from the pancreas. Procedure characteristics were recorded, including hydrogel volume and space created. Patients were monitored for adverse events (AEs) and radiotherapy toxicity. Results In all six intent-to-treat patients (four with borderline resectable, two with locally advanced disease), the ability to place and visualize PEG hydrogel and create space between the duodenum and the head of the pancreas was successful. There were no procedure-related AEs resulting in radiotherapy delay. There were no device-related AEs and no reports of pancreatitis. Conclusions PEG hydrogel was successfully placed, created space between the duodenum and the head of the pancreas, and was not associated with major toxicity. Enhancing radiotherapy for pancreatic cancer by using PEG hydrogel to create peri-duodenal space could have beneficial implications for treatment and warrants more exploration.


  • Open Access

    Balloon catheter-assisted rescue for misplacement of lumen-apposing stent across the pylorus in endoscopic ultrasound-guided transduodenal drainage of walled-off necrosis

    by Min Jae Yang, Woohyun Cho, Jae Chul Hwang, Byung Moo Yoo, Jin Hong Kim, Eun Ji Shin

    A 57-year-old man presented with a walled-off necrosis after endoscopic papillectomy. Endoscopic ultrasound-guided transduodenal drainage was attempted using a lumen-apposing metal stent (SPAXUS; TaeWoong Medical, Gimpo-si, South Korea) [1]. The proximal flange was deployed in the necrotic cavity and an enteral flange was deployed within the working channel of the echoendoscope. The stent was ejected from the working channel by pushing the stent delivery system. However, the enteral flange was positioned in the gastric antrum across the pyloric ring because the endoscope tip in the duodenum moved backward into the gastric antrum due to the reaction force generated by pushing the stent delivery system to eject the intrascope channel stent portion ([Fig. 1], [Fig. 2] a). A double-channel gastroscope (GIF-2T240; Olympus, Tokyo, Japan) was introduced, and a balloon catheter (Quattro; Cook Medical, Bloomington, Indiana, USA) was inflated after insertion into the necrotic cavity through one channel ([Fig. 2] b). Forceps introduced through the second channel of the gastroscope were used to grasp the stent and pull it out over the balloon catheter until its proximal flange was positioned in the antrum, while the inflated balloon was kept in the cavity to secure the fistula tract ([Fig. 2] c). The balloon catheter was then retrieved with the guidewire remaining in the cavity ([Fig. 2] d). A rescue double plastic stent was advanced over the guidewire and placed ([Fig. 2] e). The lumen-apposing metal stent in the antrum was retrieved from the patient’s mouth. Finally, an additional plastic stent was inserted alongside the first ([Fig. 2] f, [Video 1]). When the duodenal puncture site is close to the pyloric ring during endoscopic ultrasound-guided transduodenal intervention, the echoendoscope tip should be adequately supported to ensure that it does not retract into the gastric antrum while ejecting the intrascope channel stent portion. Additionally, the echoendoscope should be twisted in the duodenal bulb to secure adequate space for stent positioning. Endoscopy_UCTN_Code_CPL_1AL_2AD Article published online: 07 August 2024 © 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/). Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

  • Open Access

    Clinical features and outcomes of advanced HER2+ esophageal/GEJ cancer with brain metastasis

    by K. Liang, J.L. Feliciano, K.A. Marrone, J.C. Murray, C.L. Hann, V. Anagnostou, S.A. Tackett, E.J. Shin, R.K. Hales, K.R. Voong, et al.